Roivant, Priovant Announce Positive Brepocitinib Trial Results
Roivant and Priovant announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis, setting the stage for a potential new treatment that could challenge existing systemic therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed